Incannex Healthcare
AU:
IHL-AUD
A$0.04
0.00%
Incannex Healthcare is a drug manufacturers - specialty & generic business based in Australia. Incannex Healthcare shares (IHL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Incannex Healthcare has a trailing 12-month revenue of around $1 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Incannex Healthcare
To buy shares listed in Australia such as Incannex Healthcare, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
-
Open and fund your brokerage account. Complete an application with your personal and financial details, including your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
-
Search for Incannex Healthcare. Find the share by name or ticker symbol: IHL. Research its history to confirm it's a solid investment against your financial goals.
-
Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Incannex Healthcare reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
-
Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
-
Check on your investment. Congratulations, you own a part of Incannex Healthcare. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Finder Award
Our top pick for
Australian stocks
Finder Award
Incannex Healthcare stock price (ASX:IHL)
Use our graph to track the performance of IHL stocks over time.Incannex Healthcare shares at a glance
Information last updated 2023-12-28.
| 52-week range | $0.041 - $0.14 |
|---|---|
| 50-day moving average | $0.058 |
| 200-day moving average | $0.097 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.3 |
Compare share trading platforms
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
1 - 6 of 31
Is it a good time to buy Incannex Healthcare stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Incannex Healthcare price performance over time
Historical closes compared with the last close of A$0.041
| 6 months (2023-10-20) | -31.67% |
|---|
| 1 year (2023-04-20) | -65.83% |
|---|---|
| 2 years (2022-04-20) | -90.99% |
| 3 years (2021-04-20) | -86.33% |
| 5 years (2019-04-18) | 78.26% |
Incannex Healthcare financials
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $1 million |
| Return on assets TTM | -17.5% |
| Return on equity TTM | -33.3% |
| Profit margin | 0% |
| Book value | 0.053 |
| Market capitalisation | $65.1 million |
TTM: trailing 12 months
Incannex Healthcare share dividends
We're not expecting Incannex Healthcare to pay a dividend over the next 12 months.
Have Incannex Healthcare's shares ever split?
Incannex Healthcare's shares were split on a 1:20 basis on 28 July 2016. So if you had owned 20 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Incannex Healthcare shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Incannex Healthcare shares which in turn could have impacted Incannex Healthcare's share price.
Incannex Healthcare share price volatility
Over the last 12 months, Incannex Healthcare's shares have ranged in value from as little as $0.041 up to $0.14. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Incannex Healthcare's is 2.088. This would suggest that Incannex Healthcare's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Incannex Healthcare overview
Incannex Healthcare Limited, a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Docklands, Australia.
Stocks similar to Incannex Healthcare
AMP Ltd Preferred
AUD104.61
-AUD0 (0.00%)
ANZ Group Holdings Ltd. Pfd.
AUD104.30
+AUD0.49 (0.50%)
Challenger Ltd Preferred
AUD105.12
-AUD0.46 (-0.49%)
Macquarie Bank Ltd Pref
AUD106.02
+AUD0.20 (0.21%)
Macquarie Group Ltd Pref C
AUD103.11
-AUD0.04 (-0.04%)
Macquarie Group Ltd Pref
AUD105.59
-AUD0.37 (-0.39%)
Macquarie Group Preferred
AUD102.90
+AUD0.10 (0.10%)
Macquarie Group Limited
AUD106.10
+AUD0.68 (0.72%)
Westpac Banking Corp Pref
AUD103.15
+AUD0.08 (0.08%)
Whitefield Ltd Pref B
AUD98.62
-AUD0 (0.00%)
Incannex Healthcare in the news
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
Incannex thrilled with positive pre-IND meeting for arthritis treatment
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
-
How to invest in the Tasmea Limited IPO
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
-
How to buy Blinklab shares
Steps to owning and managing Blinklab shares.
-
How to invest in the Maverick Minerals IPO
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
-
How to buy Far Northern Resources shares
Steps to owning and managing Far Northern Resources shares.
-
What are the best commodity ETFs on the ASX in 2024?
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
-
Best performing stocks on the ASX in 2024 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
-
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
-
Superhero review: ASX and US share trading app
Trade ASX stocks and ETFs with a flat $2 brokerage fee and a low minimum investment of just $10.
-
The cheapest ETFs on the ASX
These ETFs have the lowest fees on the market, but does that make them the best?
-
Alternatives to CommSec: 7 trading platforms to consider
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Ask a Question